Interindividual differences in caffeine metabolism and factors driving caffeine consumption

A Nehlig - Pharmacological reviews, 2018 - ASPET
Most individuals adjust their caffeine intake according to the objective and subjective effects
induced by the methylxanthine. However, to reach the desired effects, the quantity of …

[HTML][HTML] Neuroprotective effects of coffee bioactive compounds: a review

K Socała, A Szopa, A Serefko, E Poleszak… - International journal of …, 2020 - mdpi.com
Coffee is one of the most widely consumed beverages worldwide. It is usually identified as a
stimulant because of a high content of caffeine. However, caffeine is not the only coffee …

Clinical studies on drug–drug interactions involving metabolism and transport: methodology, pitfalls, and interpretation

A Tornio, AM Filppula, M Niemi… - Clinical Pharmacology …, 2019 - Wiley Online Library
Many drug–drug interactions (DDI s) are based on alterations of the plasma concentrations
of a victim drug due to another drug causing inhibition and/or induction of the metabolism or …

Inhibition and induction of human cytochrome P450 enzymes: current status

O Pelkonen, M Turpeinen, J Hakkola, P Honkakoski… - Archives of …, 2008 - Springer
Variability of drug metabolism, especially that of the most important phase I enzymes or
cytochrome P450 (CYP) enzymes, is an important complicating factor in many areas of …

Pharmacokinetics and metabolism of natural methylxanthines in animal and man

BB Fredholm, MJ Arnaud - Methylxanthines, 2011 - Springer
Caffeine, theophylline, theobromine, and paraxanthine administered to animals and humans
distribute in all body fluids and cross all biological membranes. They do not accumulate in …

Structure, function, regulation and polymorphism and the clinical significance of human cytochrome P450 1A2

SF Zhou, B Wang, LP Yang, JP Liu - Drug metabolism reviews, 2010 - Taylor & Francis
Human CYP1A2 is one of the major CYPs in human liver and metabolizes a number of
clinical drugs (eg, clozapine, tacrine, tizanidine, and theophylline; n> 110), a number of …

Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development

SF Zhou, ZW Zhou, LP Yang… - Current medicinal …, 2009 - ingentaconnect.com
Cytochrome P450 2C9 (CYP2C9) is one of the most abundant CYP enzymes in the human
liver. CYP2C9 metabolizes more than 100 therapeutic drugs, including tolbutamide …

Mechanism-based inactivation of cytochrome P450 enzymes: chemical mechanisms, structure-activity relationships and relationship to clinical drug-drug interactions …

AS Kalgutkar, RS Obach, TS Maurer - Current drug metabolism, 2007 - ingentaconnect.com
Cytochrome P450 constitute a superfamily of heme-containing enzymes that catalyze the
oxidative biotransformation of structurally diverse xenobiotics including drugs. Inhibition of …

Synthetic and natural compounds that interact with human cytochrome P450 1A2 and implications in drug development

B Wang, SF Zhou - Current medicinal chemistry, 2009 - ingentaconnect.com
Human cytochrome P450 1A2 (CYP1A2) is one of the major CYPs in the liver (&sim13%)
and metabolizes about 20% of clinically used drugs. CYP1A2 is a 515-residue protein with a …

[HTML][HTML] Cytochrome P450 family 1 inhibitors and structure-activity relationships

J Liu, J Sridhar, M Foroozesh - Molecules, 2013 - mdpi.com
With the widespread use of O-alkoxyresorufin dealkylation assays since the 1990s,
thousands of inhibitors of cytochrome P450 family 1 enzymes (P450s 1A1, 1A2, and 1B1) …